Table 5 Summary of plasma robenacoxib concentrations (mean ± SD) 0.75 and 4 h after repeated oral and subcutaneous (SC) administration
Group | |||||||
|---|---|---|---|---|---|---|---|
1X | 2X | 3X | |||||
Hour(h) | Hour(h) | Hour(h) | |||||
0.75 | 4 | 0.75 | 4 | 0.75 | 4 | ||
Study Day | route | Mean ± SD(ng/mL) | Mean ± SD(ng/mL) | Mean ± SD(ng/mL) | Mean ± SD(ng/mL) | Mean ± SD(ng/mL) | Mean ± SD(ng/mL) |
4 | oral | 2593.1 ± 909.5 | 22.9 ± 11.6 | 5177.5 ± 2229.5 | 54.2 ± 28.5 | 5511.8 ± 3389.8 | 98.0 ± 48.6 |
7 | oral | 2591.3 ± 875.5 | 26.9 ± 27.4 | 3383.8 ± 1818.8 | 67.8 ± 58.5 | 7267.5 ± 4006.6 | 76.2 ± 32.2 |
8 | SC | NS | 98.2 ± 60.7 | NS | 233.6 ± 215.8 | NS | 723.3 ± 250.8 |
10 | SC | 1124.1 ± 325.9 | 79.1 ± 51.5 | 1481.3 ± 359.7 | 263.1 ± 249.4 | 2461.3 ± 1075.8 | 390.2 ± 236.2 |
11 | oral | NS | 34.9 ± 36.2 | NS | 66.6 ± 57.4 | NS | 99.2 ± 36.3 |
14 | oral | NS | 19.0 ± 7.3 | NS | 53.8 ± 59.0 | NS | 79.1 ± 38.0 |
17 | oral | 2811.3 ± 1502.1 | 42.7 ± 49.7 | 4160.0 ± 1166.0 | 64.5 ± 54.7 | 5798.8 ± 3218.0 | 108.5 ± 67.8 |
28 | SC | NS | 117.2 ± 86.1 | NS | 236.6 ± 130.2 | NS | 394.8 ± 187.7 |
30 | SC | 1358.6 ± 254.5 | 94.8 ± 68.3 | 1821.6 ± 817.9 | 326.0 ± 276.7 | 2878.8 ± 831.4 | 418.7 ± 246.2 |
31 | oral | NS | 27.2 ± 16.0 | NS | 101.5 ± 152.6 | NS | 94.7 ± 69.7 |
34 | oral | NS | 35.3 ± 28.5 | NS | 92.2 ± 58.5 | NS | 84.2 ± 30.3 |
37 | oral | 2717.6 ± 1589.6 | 90.4 ± 106.6 | 4009.4 ± 1765.2 | 80.0 ± 62.6 | 6460.0 ± 3839.3 | 123.2 ± 121.7 |